NCT00633724View on ClinicalTrials.gov

Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Non Small Cell Lung Cancer
Interventions
BIOLOGICAL

HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2

Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 0.5mg, 1.0mg and 3.0mg.

Trial Locations (1)

960-1295

Fukushima Medical University Hospital, Fukushima

All Listed Sponsors
collaborator

Human Genome Center, Institute of Medical Science, University of Tokyo

OTHER

lead

Fukushima Medical University

OTHER

NCT00633724 - Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter